Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Molecules › Semaglutide

Semaglutide

GLP-1 · s.c. / oral · Novo Nordisk

Data cut 12 November 2026 · page built 16 November 2026 · 5 trial arms · 14 trials with results · 155 registered trials · see on the pipeline board

Summary

Also known as
Wegovy / Ozempic / Rybelsus
Mechanism
GLP-1
Route
s.c. / oral
Company
Novo Nordisk
Highest development stage
approved
Status (as of data cut)
Approved: obesity, T2D, MACE reduction, CKD in T2D (Ozempic), MASH (Wegovy US 2025; Kayshild EU 2026); oral Wegovy tablets verify
Next milestone
7.2 mg (STEP UP)

Sources for the status

Indications: regulatory and evidence status

IndicationCodeStatusEvidence
Obesity4 approved / in labelFDA: Wegovy (injection and tablets); EMA: WegovyWegovy US label (2026); Wegovy EPAR
T2D4 approved / in labelFDA: Ozempic, Rybelsus; EMA: Ozempic, RybelsusOzempic EPAR
CV outcomes4 approved / in labelFDA label: MACE reduction in T2D with CVD (Ozempic, SUSTAIN-6/SOUL) and in obesity with CVD (Wegovy, SELECT)SELECT; SOUL; SUSTAIN-6
CKD4 approved / in labelFDA label (Ozempic): reduce risk of kidney failure, eGFR decline and CV death in T2D with CKDFLOW
HFpEF3 positive phase 3Positive phase 3 on symptoms and function; not a labelled indicationSTEP-HFpEF; STEP-HFpEF DM
MASH4 approved / in labelFDA: Wegovy, accelerated approval (MASH F2–F3, 2025); EMA: Kayshild (2026); NMPA (China): Wegovy, September 2026Wegovy US label; Kayshild EPAR; ESSENCE; NMPA approval in China (Yicai, 10 Sep 2026)
Sleep apnoea0 no dataNo phase 3 in sleep apnoea registered
Knee OA3 positive phase 3Positive phase 3 (pain and weight); not a labelled indicationSTEP 9
Alzheimer's-1 negative phase 3/4evoke and evoke+ did not meet the primary endpointevoke; evoke+

4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.

US prescribing information: indications

Verbatim section 1 of the current FDA label (DailyMed), as checked by the atlas.

OZEMPIC US label 30.01.2026

1 INDICATIONS AND USAGE RYBELSUS and OZEMPIC tablets are indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. • to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events. RYBELSUS and OZEMPIC tablets are glucagon-like peptide-1 (GLP-1) receptor agonists indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events. ( 1 )

DailyMed

Ozempic US label 30.07.2026

1 INDICATIONS AND USAGE OZEMPIC is indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease. • to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease. OZEMPIC is a glucagon-like peptide 1 (GLP-1) receptor agonist indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) • to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease. ( 1 ) • to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease. ( 1 )

DailyMed

WEGOVY US label 23.04.2024

1 INDICATIONS AND USAGE WEGOVY is indicated in combination with a reduced calorie diet and increased physical activity: • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight. • to reduce excess body weight and maintain weight reduction long term in: o Adults and pediatric patients aged 12 years and older with obesity o Adults with overweight in the presence of at least one weight-related comorbid condition. Limitations of Use • WEGOVY contains semaglutide. Coadministration with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended. WEGOVY is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated in combination with a reduced calorie diet and increased physical activity: • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight (1) . • to reduce excess body weight and maintain weight reduction long term in: o Adults and pediatric patients aged 12 years and older with obesity o Adults with overweight in the presence of at least one weight-related comorbid condition (1) . Limitations of Use: • Coadministration with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommen

DailyMed

Trial arms: weight, HbA1c and tolerability

TrialArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
OASIS 4oral semaglutide 25 mgobesity64307−16.6 % vs −2.7 %
Δ −13.9 pp
−13.6 % vs −2.2 %
Δ −11.4 pp
−0.3 vs −0.16.9 vs 5.918.5 vs 25.546.6 vs 18.630.9 vs 5.93.9 vs 8.8−6.8 vs −5.4verified
STEP 1semaglutide 2.4 mgobesity681961−16.9 % vs −2.4 %
Δ −14.5 pp
−14.9 % vs −2.4 %
Δ −12.5 pp
−0.5 vs −0.17.0 vs 3.1—44.2 vs 17.424.8 vs 6.69.8 vs 6.4−6.2 vs −1.1verified
STEP 2semaglutide 2.4 mgt2d681210−10.6 % vs −3.1 %
Δ −7.5 pp
−9.6 % vs −3.4 %
Δ −6.2 pp
−1.6 vs −0.46.2 vs 3.511.6 vs 13.933.7 vs 9.221.8 vs 2.79.9 vs 9.2−3.9 vs −0.5verified
STEP UPsemaglutide 7.2 mgobesity721407−20.7 % vs −2.4 %
Δ −18.3 pp
−18.7 % vs −3.9 %
Δ −14.8 pp
−0.3 vs −0.05.4 vs 1.011.6 vs 29.4——6.8 vs 5.5−9.9 vs −4.4verified
STEP UPsemaglutide 2.4 mgobesity721407−17.5 % vs −2.4 %
Δ −15.1 pp
−15.6 % vs −3.9 %
Δ −11.7 pp
−0.3 vs −0.04.0 vs 1.011.9 vs 29.4——10.9 vs 5.5−8.7 vs −4.4verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (33)
  • semaglutide 2.4 mg · ae_dc · Table 3
    | Adverse events leading to discontinuation of drug or placebo | 92 (7.0) | 123 | 7.2 | 20 (3.1) | 23 | 2.8 |
  • semaglutide 2.4 mg · nausea · Table 3
    | Nausea | 577 (44.2) | 1068 | 62.6 | 114 (17.4) | 146 | 17.6 |
  • semaglutide 2.4 mg · vomiting · Table 3
    | Vomiting | 324 (24.8) | 636 | 37.3 | 43 (6.6) | 52 | 6.3 |
  • semaglutide 2.4 mg · sae · Table 3
    | Serious adverse events | 128 (9.8) | 164 | 9.6 | 42 (6.4) | 53 | 6.4 |
  • semaglutide 2.4 mg · hba1c · Table 2 (supportive secondary)
    | Glycated hemoglobin — percentage points | -0.45 | -0.15 | -0.29 (-0.32 to -0.26) | | |
  • semaglutide 7.2 mg · weight_eff · Results, paragraph 3; Figure 2B
    Using the trial product estimand, the mean change in bodyweight was –20·7% (SE 0·3) with semaglutide 7·2 mg
  • semaglutide 7.2 mg · weight_tp · Table 2
    –18·7% (0·4); n=950
  • semaglutide 7.2 mg · ae_dc · Results, safety paragraphs; Table 3
    Permanent discontinuation of the trial product occurred in 54 (5·4%) of 1004 participants receiving semaglutide 7·2 mg
  • semaglutide 7.2 mg · disc_any · Figure 1
    117 discontinued treatment
  • semaglutide 7.2 mg · sae · Results; Table 3
    Serious adverse events were reported by 68 (6·8%) of 1004 participants receiving semaglutide 7·2 mg
  • semaglutide 7.2 mg · hba1c · Table 2
    –0·32 (0·01); n=938
  • semaglutide 7.2 mg · sbp · Table 2
    –9·9 (0·4); n=949
  • semaglutide 2.4 mg · ae_dc · Results, Safety (text) + Table 3; safety set N=1004/201/201
    Permanent discontinuation of the trial product occurred in 54 (5·4%) of 1004 participants receiving semaglutide 7·2 mg, eight (4·0%) of 201 receiving semaglutide 2·4 mg, and two (1·0%) of 201 receiving placebo
  • semaglutide 2.4 mg · disc_any · Figure 1 trial profile
    24 discontinued treatment 8 adverse events
  • semaglutide 2.4 mg · sae · Results, Safety (text) + Table 3; safety set N=1004/201/201
    Serious adverse events were reported by 68 (6·8%) of 1004 participants receiving semaglutide 7·2 mg, 22 (10·9%) of 201 receiving semaglutide 2·4 mg, and 11 (5·5%) of 201 receiving placebo
  • semaglutide 2.4 mg · hba1c · Table 2 (supportive secondary)
    HbA1c, percentage points –0·32 (0·01); n=938 –0·30 (0·02); n=186 –0·02 (0·03); n=167
  • semaglutide 2.4 mg · sbp · Table 2 (supportive secondary, Blood pressure)
    Systolic –9·9 (0·4); n=949 –8·7 (1·0); n=188 –4·4 (0·8); n=171
  • semaglutide 2.4 mg · weight_eff · Results, paragraph 2 (Figure 2B)
    The change for the trial product estimand was −10·6% (SE 0·4) for semaglutide 2·4 mg versus −3·1% (SE 0·4) for placebo
  • semaglutide 2.4 mg · weight_tp · Table 2
    Bodyweight change from baseline to week 68 (SE), % −9·64% (0·4) −6·99% (0·4) −3·42% (0·4)
  • semaglutide 2.4 mg · ae_dc · Table 3
    Adverse events leading to trial product discontinuation 25 (6·2%) 34 6·4
  • semaglutide 2.4 mg · disc_any · Figure 1 (trial profile)
    47 discontinued treatment prematurely*
  • semaglutide 2.4 mg · nausea · Table 3
    Nausea 136 (33·7%) 249 46·7
  • semaglutide 2.4 mg · vomiting · Table 3
    Vomiting 88 (21·8%) 188 35·3
  • semaglutide 2.4 mg · sae · Table 3
    Serious adverse events 40 (9·9%) 71 13·3
  • semaglutide 2.4 mg · hba1c · Table 2
    Change from baseline to week 68 (SE) −1·6% (0·1) −1·5% (0·1) −0·4% (0·1)
  • semaglutide 2.4 mg · sbp · Table 2
    Change from baseline to week 68 (SE) −3·9 (0·7) −2·9 (0·9) –0·5 (0·8)
  • oral semaglutide 25 mg · ae_dc · Table 3
    Adverse events leading to discontinuation of semaglutide or placebo 14 (6.9) 14 5.6 6 (5.9)
  • oral semaglutide 25 mg · disc_any · Results, Participants
    243 participants (79.2%) were receiving sema- glutide or placebo at the end of the 64-week trial period — 167 (81.5%) in the oral semaglutide group and 76 (74.5%) in the placebo group; 290
  • oral semaglutide 25 mg · nausea · Table 3
    Nausea 95 (46.6) 157 62.5 19 (18.6) 27 22.2
  • oral semaglutide 25 mg · vomiting · Table 3
    Vomiting 63 (30.9) 105 41.8 6 (5.9) 6 4.9
  • oral semaglutide 25 mg · sae · Table 3
    Serious adverse events 8 (3.9) 17 6.8 9 (8.8) 13 10.7
  • oral semaglutide 25 mg · hba1c · Table 2
    Glycated hemoglobin — percentage points –0.3 –0.1 –0.2 (–0.3 to –0.2)
  • oral semaglutide 25 mg · sbp · Table 2
    Systolic blood pressure — mm Hg –6.8 –5.4 –1.4 (–4.6 to 1.8)

Outcome trials

Cardiovascular and kidney outcome trials

SELECT semaglutide 2.4 mg vs placebo · Obesity + established CVD, no diabetes · n = 17604 · 2023 verified

EndpointHR95 % CIEvents, drug vs controlStatus
3-point MACE primary
Primary composite: CV death, nonfatal MI, or nonfatal stroke (time to first event)
0.800.72–0.90569 vs 701verified
Cardiovascular death
Death from cardiovascular causes (first confirmatory secondary endpoint)
0.850.71–1.01223 vs 262verified
All-cause death
Death from any cause (third confirmatory secondary endpoint)
0.810.71–0.93375 vs 458verified
Myocardial infarction
Nonfatal myocardial infarction only (supportive secondary endpoint); fatal MI not reported separately
0.720.61–0.85234 vs 322verified
Stroke
Nonfatal stroke only (supportive secondary endpoint); fatal stroke not reported separately
0.930.74–1.15154 vs 165verified
Hospitalisation for heart failure
Hospitalization or urgent medical visit for heart failure (supportive secondary endpoint)
0.790.60–1.0397 vs 122verified
CV death or worsening HF
Heart failure composite: CV death or hospitalization or urgent medical visit for heart failure (second confirmatory secondary endpoint)
0.820.71–0.96300 vs 361verified
Kidney composite
Nephropathy composite (supportive secondary): renal death, long-term renal replacement therapy, persistent eGFR <15, persistent 50% eGFR reduction, or persisten
0.780.63–0.96155 vs 198verified
Expanded MACE (MACE + revasc. + UA)
Cardiovascular expanded composite: death from CV causes, nonfatal MI, nonfatal stroke, coronary revascularization, or unstable angina leading to hospitalization
0.800.73–0.87873 vs 1074verified
New-onset diabetes
Glycated hemoglobin level >=6.5% (glycemic threshold for diabetes) in a population without diabetes at baseline; patients randomized in error with baseline HbA1c >6.5% excluded (8800 vs 8797 analysed)
0.270.24–0.31306 vs 1059verified
Coronary revascularisation
Coronary revascularization
0.770.68–0.87473 vs 608verified
Hospitalisation for unstable angina
Unstable angina leading to hospitalization
0.870.67–1.13109 vs 124verified
Verbatim quotes (12)
  • 3-point MACE · Results, Efficacy End Points; Table 2
    occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval [CI], 0.72 to 0.90
  • Cardiovascular death · Results, Efficacy End Points; Table 2
    occurred in 223 patients (2.5%) in the semaglutide group and in 262 patients (3.0%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.71 to 1.01; P=0.07
  • All-cause death · Table 2
    Death from any cause | 375 (4.3) | 458 (5.2) | 0.81 (0.71 to 0.93)
  • Myocardial infarction · Table 2
    Nonfatal myocardial infarction | 234 (2.7) | 322 (3.7) | 0.72 (0.61 to 0.85)
  • Stroke · Table 2
    Nonfatal stroke | 154 (1.7) | 165 (1.9) | 0.93 (0.74 to 1.15)
  • Hospitalisation for heart failure · Table 2
    Hospitalization or urgent medical visit for heart failure | 97 (1.1) | 122 (1.4) | 0.79 (0.60 to 1.03)
  • CV death or worsening HF · Table 2
    Heart failure composite end point§ | 300 (3.4) | 361 (4.1) | 0.82 (0.71 to 0.96)
  • Kidney composite · Table 2
    Nephropathy composite end point‖‖ | 155 (1.8) | 198 (2.2) | 0.78 (0.63 to 0.96)
  • Expanded MACE (MACE + revasc. + UA) · Table 2, supportive secondary end points
    | Cardiovascular expanded composite end point∥ | 873 (9.9) | 1074 (12.2) | 0.80 (0.73 to 0.87) | NA |
  • New-onset diabetes · Table 2, supportive secondary end points
    | Glycated hemoglobin level ≥6.5%†† | 306 (3.5) | 1059 (12.0) | 0.27 (0.24 to 0.31) | NA |
  • Coronary revascularisation · Table 2, supportive secondary end points
    | Coronary revascularization | 473 (5.4) | 608 (6.9) | 0.77 (0.68 to 0.87) | NA |
  • Hospitalisation for unstable angina · Table 2, supportive secondary end points
    | Unstable angina leading to hospitalization | 109 (1.2) | 124 (1.4) | 0.87 (0.67 to 1.13) | NA |

FLOW semaglutide 1.0 mg vs placebo · T2D + CKD · n = 3533 · 2024 verified

EndpointHR95 % CIEvents, drug vs controlStatus
3-point MACE
Major cardiovascular events: nonfatal MI, nonfatal stroke, or CV death (confirmatory secondary outcome, time to first event)
0.820.68–0.98212 vs 254verified
Cardiovascular death
Death from cardiovascular causes (includes undetermined causes adjudicated by the committee)
0.710.56–0.89123 vs 169verified
All-cause death
Death from any cause (confirmatory secondary outcome)
0.800.67–0.95227 vs 279verified
Myocardial infarction
Nonfatal myocardial infarction only (fatal MI not separately reported)
0.800.55–1.1552 vs 64verified
Stroke
Nonfatal stroke only (fatal stroke not separately reported)
1.220.84–1.7763 vs 51verified
Major kidney disease events primary
Major kidney disease events: kidney failure (long-term dialysis, transplantation, or sustained eGFR <15), sustained ≥50% eGFR reduction from baseline, or death
0.760.66–0.88331 vs 410verified
Sustained eGFR decline (≥50 %)
Persistent >=50% reduction from baseline in eGFR (component of primary outcome; persistent = two consecutive measurements >=4 weeks apart)
0.730.59–0.89165 vs 213verified
Kidney failure (eGFR <15)
Persistent eGFR <15 ml/min/1.73 m2 (component of primary outcome)
0.800.61–1.0692 vs 110verified
Kidney failure (kidney-replacement therapy)
Initiation of kidney-replacement therapy (dialysis or transplantation; component of primary outcome)
0.840.63–1.1287 vs 100verified
Major adverse limb events
Major adverse limb event, time-to-first-event analysis
0.560.30–1.0216 vs 28verified
Verbatim quotes (10)
  • 3-point MACE · Results, Confirmatory Secondary Outcomes; Table 2; Figure 1E
    The risk of major cardiovascular events was 18% lower in the semaglutide group than in the placebo group (212 vs. 254 events; hazard ratio, 0.82; 95% CI, 0.68 to 0.98; P = 0.029)
  • Cardiovascular death · Table 2; Figure 1C
    Death from cardiovascular causes 123 (7.0) 169 (9.6) 0.71 (0.56 to 0.89)
  • All-cause death · Results, Confirmatory Secondary Outcomes; Table 2; Figure 1F
    The risk of death from any cause was 20% lower in the semaglutide group than in the placebo group (227 vs. 279 events; hazard ratio, 0.80; 95% CI, 0.67 to 0.95, P = 0.01)
  • Myocardial infarction · Table 2
    Nonfatal myocardial infarction 52 (2.9) 64 (3.6) 0.80 (0.55 to 1.15)
  • Stroke · Table 2
    Nonfatal stroke 63 (3.6) 51 (2.9) 1.22 (0.84 to 1.77)
  • Major kidney disease events · Results, Primary Outcome; Table 2; Figure 1A
    331 first events [5.8 per 100 patient-years of follow-up] vs. 410 first events [7.5 per 100 patient-years]), ... hazard ratio, 0.76; 95% confidence interval [CI], 0.66 to 0.88; P = 0.0003
  • Sustained eGFR decline (≥50 %) · Table 2, components of primary outcome
    Persistent ≥50% reduction from baseline in eGFR 165 (9.3) 213 (12.1) 0.73 (0.59 to 0.89)
  • Kidney failure (eGFR <15) · Table 2, components of primary outcome
    Persistent eGFR <15 ml/min/1.73 m2 92 (5.2) 110 (6.2) 0.80 (0.61 to 1.06)
  • Kidney failure (kidney-replacement therapy) · Table 2, components of primary outcome
    Initiation of kidney-replacement therapy 87 (4.9) 100 (5.7) 0.84 (0.63 to 1.12)
  • Major adverse limb events · Table 2 (continued), lower section
    Major adverse limb event in a time-to-first-event analysis — no. of events 16 28 0.56 (0.30 to 1.02)

SOUL oral semaglutide 14 mg vs placebo · T2D + CVD/CKD · n = 9650 · 2025 verified

EndpointHR95 % CIEvents, drug vs controlStatus
3-point MACE primary
Three-point MACE: CV death, nonfatal MI, or nonfatal stroke (time to first event)
0.860.77–0.96579 vs 668verified
Cardiovascular death
Death from cardiovascular causes
0.930.80–1.09301 vs 320verified
All-cause death
Death from any cause
0.910.80–1.02528 vs 577verified
Myocardial infarction
Fatal or nonfatal myocardial infarction
0.730.61–0.88200 vs 268verified
Stroke
Fatal or nonfatal stroke
0.950.76–1.17164 vs 171verified
Hospitalisation for heart failure
Heart failure (hospitalization for heart failure; supportive secondary outcome, labelled 'Heart failure' in Table 2)
0.860.69–1.08146 vs 167verified
CV death or worsening HF
Heart failure events: three-point composite of CV death, urgent visit for heart failure, or hospitalization for heart failure
0.900.79–1.03405 vs 443verified
Kidney composite
Major kidney disease events (first confirmatory secondary): five-point composite of CV death, kidney-related death, persistent eGFR decline of >=50%, persistent
0.910.80–1.05403 vs 435verified
Expanded MACE (MACE + revasc. + UA)
MACE five-point composite: death from CV causes, nonfatal MI, nonfatal stroke, coronary revascularization, or hospitalization for unstable angina
0.840.76–0.93670 vs 777verified
Major adverse limb events
Major adverse limb events, two-point composite: hospitalization for acute limb ischemia or hospitalization for chronic limb ischemia (confirmatory secondary)
0.710.52–0.9671 vs 99verified
Coronary revascularisation
Coronary revascularization
0.750.62–0.90200 vs 263verified
Hospitalisation for unstable angina
Hospitalization for unstable angina pectoris
0.920.67–1.2674 vs 80verified
Verbatim quotes (12)
  • 3-point MACE · Results, Primary and Confirmatory Secondary Outcomes; Table
    579 of the 4825 participants (12.0%...) in the oral semaglutide group, as compared with 668 of the 4825 participants (13.8%...) in the placebo group (hazard ratio, 0.86; 95% CI, 0.77 to 0.96
  • Cardiovascular death · Results, paragraph 2; Table 2; Figure 1B
    301 participants (6.2%) in the oral semaglutide group and 320 participants (6.6%) in the placebo group died from cardiovascular causes (hazard ratio, 0.93; 95% CI, 0.80 to 1.09)
  • All-cause death · Table 2; Results, Supportive Secondary Outcomes
    Death from any cause 528 (10.9) 2.8 577 (12.0) 3.0 0.91 (0.80–1.02)
  • Myocardial infarction · Table 2; Results, Supportive Secondary Outcomes
    Fatal or nonfatal myocardial infarction 200 (4.1) 1.1 268 (5.6) 1.4 0.73 (0.61–0.88)
  • Stroke · Table 2; Results, Supportive Secondary Outcomes
    Fatal or nonfatal stroke 164 (3.4) 0.9 171 (3.5) 0.9 0.95 (0.76–1.17)
  • Hospitalisation for heart failure · Table 2
    Heart failure 146 (3.0) 0.8 167 (3.5) 0.9 0.86 (0.69–1.08)
  • CV death or worsening HF · Table 2; Results, Supportive Secondary Outcomes
    Heart failure events, three-point composite 405 (8.4) 2.1 443 (9.2) 2.4 0.90 (0.79–1.03)
  • Kidney composite · Results, paragraph 4; Table 2; Figure 1E
    an event occurred in 403 participants (8.4%...) in the oral semaglutide group, as compared with 435 participants (9.0%...) in the placebo group (hazard ratio, 0.91; 95% CI, 0.80 to 1.05; P = 0.19)
  • Expanded MACE (MACE + revasc. + UA) · Table 2, supportive secondary outcomes
    Major adverse cardiovascular events, five-point com- posite‖ 670 (13.9) 3.6 777 (16.1) 4.3 0.84 (0.76–0.93)
  • Major adverse limb events · Table 2, confirmatory secondary outcomes
    Major adverse limb events, two-point composite¶ 71 (1.5) 0.4 99 (2.1) 0.5 0.71 (0.52–0.96)
  • Coronary revascularisation · Table 2, supportive secondary outcomes
    Coronary revascularization 200 (4.1) 1.1 263 (5.5) 1.4 0.75 (0.62–0.90)
  • Hospitalisation for unstable angina · Table 2, supportive secondary outcomes
    Hospitalization for unstable angina pectoris 74 (1.5) 0.4 80 (1.7) 0.4 0.92 (0.67–1.26)

SUSTAIN-6 semaglutide 0.5/1.0 mg vs placebo · T2D at high CV risk · n = 3297 · 2016 verified

EndpointHR95 % CIEvents, drug vs controlStatus
3-point MACE primary
First occurrence of CV death, nonfatal MI (including silent), or nonfatal stroke
0.740.58–0.95108 vs 146verified
Cardiovascular death
Death from cardiovascular causes
0.980.65–1.4844 vs 46verified
All-cause death
Death from any cause
1.050.74–1.5062 vs 60verified
Myocardial infarction
Nonfatal myocardial infarction only (fatal MI not reported separately)
0.740.51–1.0847 vs 64verified
Stroke
Nonfatal stroke only (fatal stroke not reported separately)
0.610.38–0.9927 vs 44verified
Hospitalisation for heart failure
Hospitalization for heart failure
1.110.77–1.6159 vs 54verified
Kidney composite
New or worsening nephropathy: persistent macroalbuminuria, persistent doubling of serum creatinine with creatinine clearance <45 ml/min/1.73 m2 (MDRD), or need
0.640.46–0.8862 vs 100verified
Expanded MACE (MACE + HF hosp. + revasc. + UA)
Expanded composite: death from CV causes, nonfatal MI, nonfatal stroke, revascularization (coronary or peripheral), and hospitalization for unstable angina or heart failure
0.740.62–0.89199 vs 264verified
Retinopathy complications
Diabetic retinopathy complications: vitreous hemorrhage, onset of diabetes-related blindness, or need for treatment with an intravitreal agent or retinal photocoagulation
1.761.11–2.7850 vs 29verified
Coronary revascularisation
Revascularization (coronary or peripheral; not coronary-only)
0.650.50–0.8683 vs 126verified
Hospitalisation for unstable angina
Hospitalization for unstable angina pectoris
0.820.47–1.4422 vs 27verified
Verbatim quotes (11)
  • 3-point MACE · Results, Cardiovascular Outcomes, paragraph 1; Table 2
    The composite primary outcome occurred in 108 of 1648 patients (6.6%) in the semaglutide group and 146 of 1649 (8.9%) in the placebo group (hazard ratio, 0.74; 95% confidence interval [CI], 0.58 to 0.95
  • Cardiovascular death · Results, Cardiovascular Outcomes, paragraph 1; Table 2
    deaths reported in 44 patients (2.7%) in the semaglutide group and 46 (2.8%) in the placebo group (hazard ratio, 0.98; 95% CI, 0.65 to 1.48; P = 0.92)
  • All-cause death · Table 2
    From any cause 62 (3.8) 1.82 60 (3.6) 1.76 1.05 (0.74–1.50) 0.79
  • Myocardial infarction · Results, Cardiovascular Outcomes, paragraph 1; Table 2
    Nonfatal myocardial infarction occurred in 47 patients (2.9%) in the semaglutide group and 64 (3.9%) in the placebo group (hazard ratio, 0.74; 95% CI, 0.51 to 1.08; P = 0.12)
  • Stroke · Results, Cardiovascular Outcomes, paragraph 1; Table 2
    Nonfatal stroke occurred in 27 patients (1.6%) in the semaglutide group and 44 (2.7%) in the placebo group (hazard ratio, 0.61; 95% CI, 0.38 to 0.99; P = 0.04)
  • Hospitalisation for heart failure · Table 2
    Hospitalization for heart failure 59 (3.6) 1.76 54 (3.3) 1.61 1.11 (0.77–1.61) 0.57
  • Kidney composite · Results, Microvascular Outcomes; Table 2
    New or worsening nephropathy occurred in 62 patients (3.8%) in the semaglutide group and 100 (6.1%) in the placebo group (hazard ratio, 0.64; 95% CI, 0.46 to 0.88; P = 0.005)
  • Expanded MACE (MACE + HF hosp. + revasc. + UA) · Table 2
    Expanded composite outcome‡ 199 (12.1) 6.17 264 (16.0) 8.36 0.74 (0.62–0.89)
  • Retinopathy complications · Table 2
    Retinopathy complications§ 50 (3.0) 1.49 29 (1.8) 0.86 1.76 (1.11–2.78)
  • Coronary revascularisation · Table 2
    Revascularization 83 (5.0) 2.50 126 (7.6) 3.85 0.65 (0.50–0.86)
  • Hospitalisation for unstable angina · Table 2
    Hospitalization for unstable angina pectoris 22 (1.3) 0.65 27 (1.6) 0.80 0.82 (0.47–1.44)

PIONEER 6 oral semaglutide 14 mg vs placebo · T2D at high CV risk · n = 3183 · 2019 verified

EndpointHR95 % CIEvents, drug vs controlStatus
3-point MACE primary
First occurrence of CV death (including undetermined causes), nonfatal MI, or nonfatal stroke
0.790.57–1.1161 vs 76verified
Cardiovascular death
Death from cardiovascular causes (including undetermined causes)
0.490.27–0.9215 vs 30verified
All-cause death
Death from any cause
0.510.31–0.8423 vs 45verified
Myocardial infarction
Nonfatal myocardial infarction (first events; fatal MI not separately reported)
1.180.73–1.9037 vs 31verified
Stroke
Nonfatal stroke (first events; fatal stroke not separately reported)
0.740.35–1.5712 vs 16verified
Hospitalisation for heart failure
Heart failure resulting in hospitalization (first events)
0.860.48–1.5521 vs 24verified
Expanded MACE (MACE + HF hosp. + UA)
Expanded composite: death from CV causes, nonfatal MI, nonfatal stroke, unstable angina resulting in hospitalization, or heart failure resulting in hospitalization
0.820.61–1.1083 vs 100verified
Hospitalisation for unstable angina
Unstable angina resulting in hospitalization
1.560.60–4.0111 vs 7verified
Verbatim quotes (8)
  • 3-point MACE · Abstract; Results, Cardiovascular Outcomes; Table 2
    Major adverse cardiovascular events occurred in 61 of 1591 patients (3.8%) in the oral semaglutide group and 76 of 1592 (4.8%) in the placebo group (hazard ratio, 0.79; 95% confidence interval [CI], 0.57 to 1.11
  • Cardiovascular death · Abstract; Table 2
    death from cardiovascular causes, 15 of 1591 patients (0.9%) in the oral semaglutide group and 30 of 1592 (1.9%) in the placebo group (hazard ratio, 0.49; 95% CI, 0.27 to 0.92)
  • All-cause death · Abstract; Table 2
    Death from any cause occurred in 23 of 1591 patients (1.4%) in the oral semaglutide group and 45 of 1592 (2.8%) in the placebo group (hazard ratio, 0.51; 95% CI, 0.31 to 0.84)
  • Myocardial infarction · Abstract; Table 2
    nonfatal myocardial infarction, 37 of 1591 patients (2.3%) and 31 of 1592 (1.9%), respectively (hazard ratio, 1.18; 95% CI, 0.73 to 1.90)
  • Stroke · Abstract; Table 2
    nonfatal stroke, 12 of 1591 patients (0.8%) and 16 of 1592 (1.0%), respectively (hazard ratio, 0.74; 95% CI, 0.35 to 1.57)
  • Hospitalisation for heart failure · Results, Cardiovascular Outcomes, paragraph 3; Table 2
    First events of heart failure resulting in hospitalization occurred in 21 of 1591 patients (1.3%) and 24 of 1592 (1.5%), respectively (hazard ratio, 0.86; 95% CI, 0.48 to 1.55).
  • Expanded MACE (MACE + HF hosp. + UA) · Table 2
    Expanded composite outcome§ 83 (5.2) 4.0 100 (6.3) 4.9 0.82 (0.61–1.10)
  • Hospitalisation for unstable angina · Table 2
    Unstable angina resulting in hospitalization 11 (0.7) 0.5 7 (0.4) 0.3 1.56 (0.60–4.01)

Other indications

STEP-HFpEF Semaglutide · HFpEF + obesity · 52 weeks · n = 529 seed

KCCQ-CSS +7.8 points vs placebo; weight −13.3 % vs −2.6 %

MeasureDrugControlDifference (95 % CI)Status
Body weight, percent change from baseline
week 52
−13.3−2.6−10.7 (−11.9 to −9.4) percentage pointsverified
KCCQ clinical summary score, change from baseline
week 52
+16.6+8.7+7.8 (+4.8 to +10.9) points (0-100)verified
Verbatim quotes (2)
  • Body weight, percent change from baseline
    the mean percentage change in body weight was -13.3% with semaglutide and -2.6% with placebo (estimated difference, -10.7 percentage points; 95% CI, -11.9 to -9.4; P<0.001)
  • KCCQ clinical summary score, change from baseline
    The mean change in the KCCQ-CSS was 16.6 points with semaglutide and 8.7 points with placebo (estimated difference, 7.8 points; 95% confidence interval [CI], 4.8 to 10.9; P<0.001)

STEP-HFpEF DM Semaglutide · HFpEF + obesity + T2D · 52 weeks · n = 616 seed

KCCQ-CSS +7.3 points vs placebo

MeasureDrugControlDifference (95 % CI)Status
Body weight, percent change from baseline
week 52
−9.8−3.4−6.4 (−7.6 to −5.2) percentage pointsverified
KCCQ clinical summary score, change from baseline
week 52
+13.7+6.4+7.3 (+4.1 to +10.4) points (0-100)verified
Verbatim quotes (2)
  • Body weight, percent change from baseline
    the mean percentage change in body weight was -9.8% with semaglutide and -3.4% with placebo (estimated difference, -6.4 percentage points; 95% CI, -7.6 to -5.2; P<0.001)
  • KCCQ clinical summary score, change from baseline
    The mean change in the KCCQ-CSS was 13.7 points with semaglutide and 6.4 points with placebo (estimated difference, 7.3 points; 95% confidence interval [CI], 4.1 to 10.4; P<0.001)

STEP 9 Semaglutide · Knee osteoarthritis + obesity · 68 weeks · n = 407 seed

WOMAC pain −41.7 vs −27.5 points; weight −13.7 % vs −3.2 %

ESSENCE (part 1) Semaglutide · MASH F2–F3 · 72 weeks · n = 800 seed

Steatohepatitis resolution 62.9 % vs 34.3 %; fibrosis improvement 36.8 % vs 22.4 %; FDA accelerated approval 2025

MeasureDrugControlDifference (95 % CI)Status
Reduction in liver fibrosis (>=1 stage) without worsening of steatohepatitis
week 72
+36.8+22.4+14.4 (+7.5 to +21.3) percentage pointsverified
Resolution of steatohepatitis without worsening of fibrosis
week 72
+62.9+34.3+28.7 (+21.1 to +36.2) percentage pointsverified
Verbatim quotes (2)
  • Reduction in liver fibrosis (>=1 stage) without worsening of steatohepatitis
    A reduction in liver fibrosis without worsening of steatohepatitis was reported in 36.8% of the patients in the semaglutide group and in 22.4% of those in the placebo group (estimated difference, 14.4 percentage points; 95% CI, 7.5 to 21.3; P<0.001)
  • Resolution of steatohepatitis without worsening of fibrosis
    Resolution of steatohepatitis without worsening of fibrosis occurred in 62.9% of the 534 patients in the semaglutide group and in 34.3% of the 266 patients in the placebo group (estimated difference, 28.7 percentage points; 95% confidence interval [CI], 21.1 to 36.2; P<0.001)

FLOW Semaglutide · CKD + T2D · 178 weeks · n = 3533 seed

Major kidney events HR 0.76; all-cause death HR 0.80

MeasureDrugControlDifference (95 % CI)Status
Major kidney disease events (kidney failure, >=50% eGFR reduction, kidney or CV death)
week 177
+331.0+410.0+0.8 (+0.7 to +0.9) hazard ratioverified
Verbatim quotes (1)
  • Major kidney disease events (kidney failure, >=50% eGFR reduction, kidney or CV death)
    The risk of a primary-outcome event was 24% lower in the semaglutide group than in the placebo group (331 vs. 410 first events; hazard ratio, 0.76; 95% confidence interval [CI], 0.66 to 0.88; P = 0.0003)

evoke / evoke+ Semaglutide · Early Alzheimer's disease · 104 weeks · n = 3680 seed

Primary endpoint (CDR-SB) not met (announced Nov 2025)

MeasureDrugControlDifference (95 % CI)Status
CDR-SB, change from baseline evoke
week 104
+2.3+2.3−0.1 (−0.3 to +0.2) points (0-18)verified
CDR-SB, change from baseline evoke+
week 104
+2.2+2.1+0.1 (−0.2 to +0.4) points (0-18)verified
Verbatim quotes (2)
  • CDR-SB, change from baseline
    mean changes in CDR-SB score from baseline to week 104 were 2·3 (SE 0·1) and 2·2 (0·1) with semaglutide, compared with 2·3 (0·1) and 2·1 (0·1) with placebo (estimated difference -0·08 [95% CI -0·35 to 0·20], p=0·57 in evoke and 0·10 [-0·17 to 0·38], p=0·46 in evoke+)
  • CDR-SB, change from baseline
    mean changes in CDR-SB score from baseline to week 104 were 2·3 (SE 0·1) and 2·2 (0·1) with semaglutide, compared with 2·3 (0·1) and 2·1 (0·1) with placebo (estimated difference -0·08 [95% CI -0·35 to 0·20], p=0·57 in evoke and 0·10 [-0·17 to 0·38], p=0·46 in evoke+)

Registered trials (155)

From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.

TrialIndicationPhaseStatusStart → primary completionnResultRegistry
NCT07797036
Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes Mellitus
OtherPhase 3not yet recruiting2027-09 → 2030-09226not yet recruitingNCT07797036
S-CUD
Semaglutide for the Treatment of Cannabis Use Disorder
AddictionPhase 2not yet recruiting2027-01 → 2029-0140not yet recruitingNCT07879612
VITAL-H
Validation & Intervention Testing for Aging, Longevity and Healthspan
OtherPhase 2not yet recruiting2027-01 → 2030-121200not yet recruitingNCT07923630
SPOT-DM
Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus
OtherPhase 3not yet recruiting2026-12 → 2029-0637not yet recruitingNCT06913023
NCT07642635
Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy
OtherPhase 2recruiting2026-12 → 2030-0930recruitingNCT07642635
ESCaMS Trial
Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome
OtherPhase 3not yet recruiting2026-12 → 2030-07600not yet recruitingNCT07770282
SEMAFORCRANIO
SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years
ObesityPhase 3not yet recruiting2026-11 → 2031-0250not yet recruitingNCT07845994
LEAST
Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy
NeurologyPhase 2not yet recruiting2026-10 → 2028-10100not yet recruitingNCT07511543
WE-FiERCE
Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the Endometrium
OtherPhase 2recruiting2026-09 → 2029-0271recruitingNCT06073184
NCT06934655
Early Reinitiation of Semaglutide Post-Sleeve Gastrectomy in Youth
ObesityPhase 3recruiting2026-09 → 2030-11150recruitingNCT06934655
SHIFT
Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study
AddictionPhase 2not yet recruiting2026-09 → 2027-0140not yet recruitingNCT07509112
NCT07651319
Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease
Alzheimer'sPhase 2recruiting2026-09 → 2029-0630recruitingNCT07651319
UNIGUIDE-2
Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)
T2DPhase 3recruiting2026-09 → 2028-02956recruitingNCT07653477
OASIS 5
Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
ObesityPhase 3recruiting2026-08 → 2028-02450recruitingNCT07770841
CRAVE
Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE)
AddictionPhase 3recruiting2026-07 → 2029-03622recruitingNCT07218354
PLASTIC
Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity
ObesityPhase 3not yet recruiting2026-06 → 2031-04120not yet recruitingNCT07021937
NCT07282769
Semaglutide (Wegovy) Treatment for Trichotillomania
OtherPhase 2not yet recruiting2026-06 → 2027-0210not yet recruitingNCT07282769
GLICH
GLP-1 Receptor Agonist in Primary Intracerebral Hemorrhage: A Phase 2 Randomized Trial
NeurologyPhase 2not yet recruiting2026-06 → 2028-06200not yet recruitingNCT07613437
GLOW
Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes
T2DPhase 3recruiting2026-05 → 2028-1120recruitingNCT07428746
GL1DER HIV RCT
GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV
AddictionPhase 2recruiting2026-04 → 2029-10200recruitingNCT07221214
NCT07466017
A Study of CS060380 Tablets in Patients With MASH and Obesity
MASHPhase 2active not recruiting2026-04 → 2027-04130active not recruitingNCT07466017
HASHTAG
Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder
AddictionPhase 2recruiting2026-04 → 2028-04100recruitingNCT07523633
SEMAFOOT2
Effect of Semaglutide on Healing of Foot Ulcers in Type 2 Diabetes Patients
T2DPhase 3recruiting2026-04 → 2028-1252recruitingNCT07581145
NCT06975111
Focusing on the Menopausal Transition to Improve Mid-Life Women's Health
OtherPhase 3recruiting2026-03 → 2029-10200recruitingNCT06975111
GLP1-SC
Semaglutide for Smoking Cessation in Patients With Diabetes
AddictionPhase 3recruiting2026-02 → 2026-12100recruitingNCT07059377
GEM
Glutide for Ending Methamphetamine
AddictionPhase 2recruiting2026-02 → 2030-02162recruitingNCT07204249
REST
Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: Recovery Effects After Semaglutide Termination
ObesityPhase 3recruiting2026-02 → 2028-0998recruitingNCT07294950
REINFORCE
Incretin Microdosing for Cardiometabolic Health in People With HIV
OtherPhase 2recruiting2026-02 → 2028-0530recruitingNCT07325500
HARP
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide
AddictionPhase 2recruiting2026-01 → 2027-0630recruitingNCT07040592
NCT07135245
Improved Treatment and Monitoring of Alzheimer's Disease
Alzheimer'sPhase 2not yet recruiting2026-01 → 2030-09180not yet recruitingNCT07135245
NCT07227948
Repurposing Semaglutide for the Treatment of Cocaine Use Disorder
AddictionPhase 2recruiting2026-01 → 2029-0175recruitingNCT07227948
NCT07271251 · Japan
A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 Diabetes
T2DPhase 3completed2025-12 → 2026-06267Completed; results not in the atlas yetNCT07271251
GALACTUS
Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)
OtherPhase 3completed2025-12 → 2026-1044Completed; results not in the atlas yetNCT07295223
EPIC-CT
Epicardial Cardiac Fat-CT (EPIC-CT)
OtherPhase 3recruiting2025-12 → 2027-01136recruitingNCT07297589
NCT07820111
Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial
ObesityPhase 3completed2025-10 → 2026-03159Completed; results not in the atlas yetNCT07820111
NCT07200622
Oral Semaglutide in Patients With Alzheimer's Disease
Alzheimer'sPhase 2not yet recruiting2025-09 → 2027-1260not yet recruitingNCT07200622
STAC
Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV
AddictionPhase 2active not recruiting2025-08 → 2027-0140active not recruitingNCT06691243
STARS
Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial
NeurologyPhase 3not yet recruiting2025-07 → 2027-07436not yet recruitingNCT07030621
SHORE
Semaglutide for Helping Opioid Recovery
AddictionPhase 2recruiting2025-06 → 2027-0946recruitingNCT06639464
SYNCARDIA-HF
Effects of Dapagliflozin, Semaglutide, and Their Combination in Heart Failure Patients With Prosthetic Heart Valves
HFpEFPhase 2completed2025-06 → 2026-04160Completed; results not in the atlas yetNCT07610174
SEMINAL-AF
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
ObesityPhase 3recruiting2025-04 → 2027-12200recruitingNCT06499857
PCOS
Semaglutide vs Metformin in Polycystic Ovary Syndrome (PCOS)
ObesityPhase 3unknown2025-03 → 2025-0960unknownNCT05646199
NCT06738979
A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects
ObesityPhase 3completed2025-03 → 2026-03408Completed; results not in the atlas yetNCT06738979
SEMPSO
Effect of Semaglutide in Patients With Psoriasis and Obesity
ObesityPhase 3recruiting2025-03 → 2026-0714recruitingNCT06937060
GALLOP2
Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment
NeurologyPhase 3not yet recruiting2025-02 → 2028-02390not yet recruitingNCT06788626
FINESSE-CKD
Optimizing Albuminuria Treatment in CKD With Finerenone and Semaglutide
CKDPhase 2completed2025-02 → 2026-0841Completed; results not in the atlas yetNCT07819227
NCT06548490
GLP-1R Agonist Treatment for Opioid Use Disorder
AddictionPhase 2recruiting2025-01 → 2027-04200recruitingNCT06548490
NCT06896981
Semaglutide in Women With Polycystic Ovary Syndrome and Obesity
ObesityPhase 3completed2025-01 → 2025-1031Completed; results not in the atlas yetNCT06896981
NCT06717698
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
CKDPhase 2recruiting2024-12 → 2026-09465recruitingNCT06717698
NCT06616961
Efficacy and Safety of Semaglutide for Weight Loss in Overweight or Obese Adults in Bangladesh With or Without Type 2 Diabetes Mellitus
ObesityPhase 3unknown2024-11 → 2025-02480unknownNCT06616961
NCT06633783
A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®
ObesityPhase 3unknown2024-10 → 2026-05370unknownNCT06633783
CAPTIVATE
The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect
CKDPhase 3recruiting2024-09 → 2029-122000recruitingNCT06058585
NCT06604624
Semaglutide in Treatment of Obesity
ObesityPhase 3completed2024-09 → 2025-08462Completed; results not in the atlas yetNCT06604624
PROTECT
Semaglutide in Auto-HSCT
OtherPhase 2not yet recruiting2024-08 → 2026-1240not yet recruitingNCT06449625
SEMAHEART
Mechanisms of Semaglutide Therapy in Heart Failure Patients
HFpEFPhase 2unknown2024-07 → 2025-0710unknownNCT06541509
NCT06361823
Exploratory Study on the Efficacy and Safety of Semaglutide for Idiopathic Intracranial Hypertension Treatment
NeurologyPhase 3unknown2024-05 → 2024-1274unknownNCT06361823
NCT06173778
Semaglutide for Post-Smoking Cessation Weight Management
AddictionPhase 2recruiting2024-04 → 2028-05197recruitingNCT06173778
NCT06339086
Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 Diabetes
T2DPhase 3unknown2024-04 → 2025-08478unknownNCT06339086
FIT-HF
Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure
HFpEFPhase 3recruiting2024-04 → 2027-12100recruitingNCT06423599
NCT05424003
Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant
OtherPhase 2recruiting2024-02 → 2026-0850recruitingNCT05424003
NCT06161844
Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus
T2DPhase 3completed2024-02 → 2025-05506Completed; results not in the atlas yetNCT06161844
AUD
Clinical Trial of Rybelsus (Semaglutide) Among Adults With Alcohol Use Disorder (AUD)
AddictionPhase 2completed2024-01 → 2025-1150Completed; results not in the atlas yetNCT05892432
NCT06072963
COMMETS- Combination MCI Metabolic Syndrome
OtherPhase 2recruiting2024-01 → 2027-1280recruitingNCT06072963
RESTORE
Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome
ObesityPhase 3recruiting2023-11 → 2028-0280recruitingNCT05819853
NCT05788965
Semaglutide in CFRD
ObesityPhase 3completed2023-10 → 2024-128Completed; results not in the atlas yetNCT05788965
HALLMARK
The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients
CKDPhase 2recruiting2023-10 → 2027-1020recruitingNCT05938712
STAR
Semaglutide Therapy for Alcohol Reduction (STAR)
AddictionPhase 2active not recruiting2023-10 → 2027-0363active not recruitingNCT06015893
SERENA
Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes
OtherPhase 3recruiting2023-09 → 2030-03252recruitingNCT05569772
NCT05813912
A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes
T2DPhase 3completed2023-09 → 2025-04148Completed; results not in the atlas yetNCT05813912
STEP12
A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range
ObesityPhase 3completed2023-09 → 2025-04242Completed; results not in the atlas yetNCT06041217
WP3
Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study
CKDPhase 2terminated2023-08 → 2024-091TerminatedNCT05897372
GALLOP
Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies
NeurologyPhase 2completed2023-08 → 2024-10140Completed; results not in the atlas yetNCT05920889
NCT05067621
Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease
MASHPhase 2active not recruiting2023-07 → 2026-1260active not recruitingNCT05067621
STEP Young
A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight
ObesityPhase 3active not recruiting2023-07 → 2025-10212active not recruitingNCT05726227
STAR-T
Semaglutide Therapy for Alcohol Reduction - Tulsa
AddictionPhase 2completed2023-07 → 2025-0780Completed; results not in the atlas yetNCT05891587
NCT05950516
Efficacy and Safety of Semaglutide Ingection in Subjects With Type 2 Diabetes
T2DPhase 3unknown2023-07 → 2024-11478unknownNCT05950516
NCT05891496
A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease
Alzheimer'sPhase 3completed2023-06 → 2024-0823Completed; results not in the atlas yetNCT05891496
SEMALCO
Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?
AddictionPhase 2completed2023-06 → 2025-07108Completed; results not in the atlas yetNCT05895643
OASIS 3
Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3)
ObesityPhase 3completed2023-05 → 2025-01200Completed; results not in the atlas yetNCT05890976
ASSET
Acute Subcutaneous SemaglutidE in Acute Ischemic sTroke
NeurologyPhase 2recruiting2023-04 → 2025-09380recruitingNCT05630586
SURMOUNT-5
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities
ObesityPhase 3completed2023-04 → 2024-11751Completed; arm-level results are in the atlas maps (Effect vs cost, Arms)NCT05822830
KLIN-HEALTH
Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter Syndrome
OtherPhase 3recruiting2023-03 → 2027-04150recruitingNCT05586802
STEP UP
A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)
ObesityPhase 3completed2023-01 → 2024-101407Completed; arm-level results are in the atlas maps (Effect vs cost, Arms)NCT05646706
NCT05649137
A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight
ObesityPhase 3completed2023-01 → 2024-10512Completed; results not in the atlas yetNCT05649137
LSS
Latino Semaglutide Study
ObesityPhase 3completed2022-12 → 2024-05119Completed; results not in the atlas yetNCT05087342
BARI-STEP
Semaglutide 2.4 mg in Patients With Poor Weight-loss
ObesityPhase 3completed2022-11 → 2025-0470Completed; results not in the atlas yetNCT05073835
NCT05530577
Effects of Semaglutide on Nicotine Intake
AddictionPhase 2completed2022-10 → 2024-0524Completed; results not in the atlas yetNCT05530577
OASIS 4
Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range
ObesityPhase 3completed2022-10 → 2024-04307Completed; arm-level results are in the atlas maps (Effect vs cost, Arms)NCT05564117
NCT05520775
Semaglutide for Alcohol Use Disorder
AddictionPhase 2completed2022-09 → 2024-0448Completed; results not in the atlas yetNCT05520775
NCT04998136 · Korea
Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity
ObesityPhase 3completed2022-08 → 2023-10150Completed; results not in the atlas yetNCT04998136
NCT05478252
A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes
T2DPhase 3completed2022-08 → 2023-08388Completed; results not in the atlas yetNCT05478252
SUSTAIN OPTIMIZE
A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)
T2DPhase 3completed2022-08 → 2025-03573Completed; results not in the atlas yetNCT05514535
TOLEDDO
Effect of Weekly GLP1 Agonist Treatment in "Double Diabetes"
OtherPhase 3recruiting2022-07 → 2028-0876recruitingNCT05305794
NCT05816057
A Study of the Efficacy and Safety of Semaglutide Injection in the Treatment of Type 2 Diabetes Mellitus
T2DPhase 3completed2022-07 → 2023-07476Completed; results not in the atlas yetNCT05816057
COMBINE 2
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)
T2DPhase 3completed2022-04 → 2023-12683Completed; results not in the atlas yetNCT05259033
SMART
SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes
CKDPhase 3completed2022-03 → 2024-05125Completed; results not in the atlas yetNCT04889183
HISTORI
Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes
OtherPhase 2completed2022-01 → 2024-03154Completed; results not in the atlas yetNCT05193578
SEPLA
Effect Of Semaglutide In Coronary Atheroma Plaque
OtherPhase 3unknown2021-11 → 2024-12120unknownNCT05071417
OASIS 2
Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity
ObesityPhase 3completed2021-11 → 2023-07201Completed; results not in the atlas yetNCT05132088
STEP 9
Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis
Knee OAPhase 3completed2021-10 → 2023-07407WOMAC pain −41.7 vs −27.5 pointsNCT05064735
NCT04466345
Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder
Alzheimer'sPhase 2completed2021-10 → 2024-1272Completed; results not in the atlas yetNCT04466345
SEMPATICO
Semaglutide to Reduce Myocardial Injury in PATIents With COVID-19
OtherPhase 2unknown2021-09 → 2022-03400unknownNCT04615871
OASIS 1
Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1)
ObesityPhase 3completed2021-09 → 2023-03667Completed; results not in the atlas yetNCT05035095
STEP 10
Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes
ObesityPhase 3completed2021-09 → 2023-01207Completed; results not in the atlas yetNCT05040971
WAYFIND
Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
MASHPhase 2completed2021-08 → 2024-11457Completed; results not in the atlas yetNCT04971785
NCT05016882
Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)
MASHPhase 2completed2021-08 → 2024-12698Completed; results not in the atlas yetNCT05016882
RAISE-KT
Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy
CKDPhase 3terminated2021-07 → 2023-0115TerminatedNCT04741074
STEP-HFpEF DM
Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes
HFpEFPhase 3completed2021-06 → 2023-10617KCCQ-CSS +7.3 points vs placeboNCT04916470
evoke / evoke+
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)
Alzheimer'sPhase 3completed2021-05 → 2025-091840CDR-SB primary endpoint not metNCT04777396
EVOKE Plus
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)
Alzheimer'sPhase 3completed2021-05 → 2025-091840CDR-SB primary endpoint not met (with evoke)NCT04777409
ESSENCE (part 1)
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)
MASHPhase 3active not recruiting2021-04 → 2029-041205MASH resolution 62.9 % vs 34.3 %NCT04822181
REMODEL
A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
CKDPhase 3completed2021-04 → 2024-11106Completed; results not in the atlas yetNCT04865770
STEP-HFpEF
Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity
HFpEFPhase 3completed2021-03 → 2023-04529KCCQ-CSS +7.8 points vs placeboNCT04788511
The SLIM LIVER Study
Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)
MASHPhase 2completed2021-02 → 2023-0351Completed; results not in the atlas yetNCT04216589
PIONEER PLUS
Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes
T2DPhase 3completed2021-01 → 2023-031606Completed; results not in the atlas yetNCT04707469
STEP7
Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity.
ObesityPhase 3completed2020-12 → 2022-08375Completed; results not in the atlas yetNCT04251156
PIONEER TEENS
A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes
T2DPhase 3completed2020-11 → 2025-04132Completed; results not in the atlas yetNCT04596631
STRIDE
A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes
CV outcomesPhase 3completed2020-10 → 2024-06792Completed; results not in the atlas yetNCT04560998
SEMAT
The Effects of Semaglutide vs Testosterone Replacement Therapy on Functional Hypogonadism and Sperm Quality in Men With Type 2 Diabetes Mellitus and Obesity
ObesityPhase 3completed2020-09 → 2023-0525Completed; results not in the atlas yetNCT06489457
NCT04447859
16-week Flexible vs. 8-week Semaglutide Titration
T2DPhase 3unknown2020-02 → 2022-05100unknownNCT04447859
NCT04102189
A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity
ObesityPhase 3completed2019-10 → 2022-03201Completed; results not in the atlas yetNCT04102189
PIONEER 11
A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes
T2DPhase 3completed2019-10 → 2021-09521Completed; results not in the atlas yetNCT04109547
NAFLD HEROES
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
MASHPhase 2recruiting2019-07 → 2028-08104recruitingNCT03884075
NCT03987074
Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)
MASHPhase 2completed2019-07 → 2020-07109Completed; results not in the atlas yetNCT03987074
SURPASS-2
A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes
T2DPhase 3completed2019-07 → 2021-011879Completed; results not in the atlas yetNCT03987919
PIONEER 12
A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes
T2DPhase 3completed2019-07 → 2021-101441Completed; results not in the atlas yetNCT04017832
FLOW
A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease
CKDPhase 3completed2019-06 → 2024-013533Kidney composite HR 0.76 (0.66–0.88)NCT03819153
SOUL
A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes
CV outcomesPhase 3completed2019-06 → 2024-089651MACE HR 0.86 (0.77–0.96)NCT03914326
NCT03987451
A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage
MASHPhase 2completed2019-06 → 2021-0471Completed; results not in the atlas yetNCT03987451
SUSTAIN FORTE
A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes
T2DPhase 3completed2019-06 → 2020-09961Completed; results not in the atlas yetNCT03989232
FOCUS
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
T2DPhase 3active not recruiting2019-05 → 2027-111500active not recruitingNCT03811561
TEAL
Treating PCOS With Semaglutide vs Active Lifestyle Intervention
ObesityPhase 3completed2019-05 → 2023-1060Completed; results not in the atlas yetNCT03919929
GIPD
GLP1R in Parkinson's Disease
NeurologyPhase 2unknown2019-01 → 2024-12120unknownNCT03659682
STEP 6
STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity
ObesityPhase 3completed2019-01 → 2020-11401Completed; results not in the atlas yetNCT03811574
SELECT
Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity
CV outcomesPhase 3completed2018-10 → 2023-0617604MACE HR 0.80 (0.72–0.90)NCT03574597
SUSTAIN 11
A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes
T2DPhase 3completed2018-10 → 2021-022274Completed; results not in the atlas yetNCT03689374
STEP 5
Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
ObesityPhase 3completed2018-10 → 2021-01304Completed; results not in the atlas yetNCT03693430
STEP 3
Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program
ObesityPhase 3completed2018-08 → 2020-03611Completed; results not in the atlas yetNCT03611582
STEP 1
STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
ObesityPhase 3completed2018-06 → 2020-031961Completed; arm-level results are in the atlas maps (Effect vs cost, Arms)NCT03548935
STEP 4
Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
ObesityPhase 3completed2018-06 → 2020-02902Completed; results not in the atlas yetNCT03548987
STEP 2
Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity
ObesityPhase 3completed2018-06 → 2020-031210Completed; arm-level results are in the atlas maps (Effect vs cost, Arms)NCT03552757
SUSTAIN - CHINA MRCT
Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)
T2DPhase 3completed2017-08 → 2019-03868Completed; results not in the atlas yetNCT03061214
SUSTAIN 9
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus
T2DPhase 3completed2017-03 → 2018-07302Completed; results not in the atlas yetNCT03086330
SUSTAIN 8
Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes
T2DPhase 3completed2017-03 → 2018-10788Completed; results not in the atlas yetNCT03136484
PIONEER 8
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin
T2DPhase 3completed2017-02 → 2018-01731Completed; results not in the atlas yetNCT03021187
PIONEER 6
A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes
CV outcomesPhase 3completed2017-01 → 2018-093183MACE HR 0.79 (0.57–1.11): non-inferiorNCT02692716
PIONEER 10
Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes
T2DPhase 3completed2017-01 → 2018-07458Completed; results not in the atlas yetNCT03015220
NCT02970942
Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.
MASHPhase 2completed2016-11 → 2020-02320Completed; results not in the atlas yetNCT02970942
PIONEER 5
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment
T2DPhase 3completed2016-09 → 2018-04324Completed; results not in the atlas yetNCT02827708
PIONEER 7
Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.
T2DPhase 3completed2016-09 → 2018-02504Completed; results not in the atlas yetNCT02849080
PIONEER 1
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only
T2DPhase 3completed2016-09 → 2017-10703Completed; results not in the atlas yetNCT02906930
PIONEER 2
Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus
T2DPhase 3completed2016-08 → 2017-08822Completed; results not in the atlas yetNCT02863328
PIONEER 3
Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes
T2DPhase 3completed2016-02 → 2017-021864Completed; results not in the atlas yetNCT02607865
SUSTAIN 7
Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.
T2DPhase 3completed2016-01 → 2017-041201Completed; results not in the atlas yetNCT02648204
SUSTAIN-6
Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes
CV outcomesPhase 3completed2013-02 → 2016-033297MACE HR 0.74 (0.58–0.95)NCT01720446

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: Semaglutide. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/semaglutide/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.